Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

20 Feb 2019

Abstract excerpt

BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. METHODS: Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Cells and Metastasis
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30786922
DOI: 10.1186/s13148-019-0626-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patientsPMID 30786922Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast CancerSemantic proximity Read ↗

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read ↗

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read ↗

Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast CancerSemantic proximity Read ↗

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targetsSemantic proximity Read ↗

Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapySemantic proximity Read ↗

A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsSemantic proximity Read ↗

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancerSemantic proximity Read ↗

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancerSemantic proximity Read ↗

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity Read ↗

Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.